Volume 6.21 | Jun 2

Pancreatic Cell News 6.21 June 2, 2015
Pancreatic Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PACN on Twitter
Common Antibiotic Part of a Promising Potential Pancreatic Cancer Therapy
Researchers found a potent synergistic effect when they combined the drug sabutoclax and the antibiotic minocycline. The combination was significantly toxic to pancreatic cancer cells and disrupted tumor growth and extended survival in several types of advanced pancreatic cancer mouse models. [Press release from VCU Massey Cancer Center discussing online publication in Cancer Research] Press Release | Abstract
Take the "if" out of "diff": reduce variability when differentiating to definitive endoderm
PUBLICATIONS (Ranked by impact factor of the journal)

GPR43 Potentiates Beta Cell Function in Obesity
In vitro treatment of isolated murine islets, human islets and Min6 cells with PA, a specific agonist of GPR43, increased intracellular IP3 and Ca2+ levels, and potentiated insulin secretion in a GPR43, Gαq, and phospholipase C dependent manner. [Diabetes] Abstract

Fibrin Supports Human Fetal Islet-Epithelial Cell Differentiation via p70s6k and Promotes Vascular Formation during Transplantation
Researchers investigated how fibrin promotes human fetal pancreatic cell differentiation in vitro and in vivo. Fibrin-cultured human fetal pancreatic cells had significantly increased expression of PDX-1, glucagon, insulin, and VEGF-A, along with increased integrin αVβ3 and phosphorylated FAK and p70s6k. [Lab Invest] Abstract

Lactisol Inhibits the Glucose-Sensing Receptor T1R3 Expressed in Mouse Pancreatic β-Cells
Investigators examined whether or not lactisole can be used as an inhibitor of the glucose-sensing receptor. In MIN6 cells, in a dose-dependent manner, lactisole inhibited insulin secretion induced by sweeteners, acesulfame-K, sucralose and glycyrrhizin. [J Endocrinol] Abstract

FTO Inhibits Insulin Secretion and Promotes NF-κB Activation through Positively Regulating ROS Production in Pancreatic β Cells
Fat mass and obesity-associated (FTO) is widely expressed in various tissues and presented with relative high expression in pancreas tissue, especially in endocrine pancreas. FTO overexpression in MIN6 cells achieved by lentivirus delivery significantly inhibits insulin secretion in the presence of glucose stimulus as well as KCl. [PLoS One] Full Article


COSMC Knockdown Mediated Aberrant O-Glycosylation Promotes Oncogenic Properties in Pancreatic Cancer
Since the role of Tn antigen expression in pancreatic ductal adenocarcinoma (PDAC) is insufficiently understood, scientists analyzed the impact of COSMC mediated Tn antigen expression in two human PDAC cell lines on cellular oncogenic properties. [Mol Cancer] Abstract

Decreased LKB1 Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma
The authors characterized the expression pattern of liver kinase B1 (LKB1) and assess the clinical significance of LKB1 expression in pancreatic ductal adenocarcinoma (PDAC) patients. Protein expression of LKB1 was significantly reduced in six PDAC cell lines and downregulated in 31.3% of PDAC lesions compared to matched non-tumorous tissues, as determined by Western blot analysis. [Sci Rep] Full Article

PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-Phase and Enhancing DNA Damage in Pancreatic Cancer
Gemcitabine treatment stimulated endogenous protein tyrosine kinase 6 (PTK6) overexpression in MIAPaCa2 and Panc1 cells. PTK6 gene-silencing increased cell survival after gemcitabine treatment and decreased apoptosis, while PTK6 overexpression decreased cell survival and increased apoptosis. [Mol Cancer Res] Abstract

Inhibition of hTERT/Telomerase Contributes to the Antitumor Activity of Pristimerin in Pancreatic Ductal Adenocarcinoma Cells
Researchers investigated the role of telomerase in mediating the antitumor activity of pristimerin (PM) in pancreatic ductal adenocarcinoma (PDA) cells. PM inhibited cell proliferation, arrested cells in the G1 cell cycle phase and induced apoptosis in MiaPaCa-2 and Panc-1 PDA cells. [Oncol Rep] Abstract

Register Now: Webinar on Gastrointestinal Organoids by Dr. Meritxell Huch
Associated Autoimmunity in Children and Adolescents with Type 1 Diabetes Mellitus (T1DM)
The authors report on the classification of autoimmune diabetes, and on the prevalence, pathogenesis, predictive factors and clinical presentation of pancreatic autoimmunity and of all associated autoimmune disorders in children with T1DM. [Autoimmun Rev] Abstract

Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer
BerGenBio AS announced that an abstract on the latest data on BGB324, the company’s first-in-class, selective small molecule inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking monoclonal antibody in pre-clinical development at BerGenBio, has been published. [Press release from BerGenBio AS discussing research presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release | Abstract

Targovax Presented Safety Data and Immunological Results
Targovax presented safety data and immunological results from the ongoing Phase I/II clinical study CT-TG01-01, testing the therapeutic cancer vaccine TG01 in combination with gemcitabine in patients with resected pancreatic cancer. [Press release from Targovax discussing research presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release | Poster

Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies
The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio. [Press release from Boehringer Ingelheim GmbH discussing research presented at the American Diabetes Association’s® (ADA) 75th Scientific Sessions, Boston] Press Release

From our sponsor:
Webinar: Neural Stem Cell Culture Systems – Neurosphere vs. Adherent Monolayer Culture.
Watch now.
Astellas and Anokion to Collaborate on Immune Tolerance Therapeutics
Astellas Pharma Inc. and Anokion SA announced an agreement to collaborate in the fields of type 1 diabetes and celiac disease. A new company, Kanyos Bio, Inc. has been created to develop clinical candidates in the two selected indications, with an option for Astellas to add a third autoimmune indication as part of the collaboration. [Astellas Pharma Inc.] Press Release

PharmaEngine Announces Filing New Drug Application (NDA) of MM-398 (PEP02) to Taiwan FDA as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
PharmaEngine, Inc. announced that an NDA has been submitted to the Taiwan Food and Drug Administration (FDA) for MM-398 in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. [PharmaEngine, Inc.] Press Release

Halozyme Phase II Clinical Study of Investigational Drug PEGPH20 Shows Doubling of Progression-Free Survival and Improvement Trend in Overall Survival in High HA Metastatic Pancreatic Cancer Patients
Halozyme Therapeutics, Inc. announced interim findings from the ongoing Phase II clinical study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer. [Halozyme Therapeutics, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cell Symposia Meeting – Stem Cell Epigenetics
September 20-22, 2015
Sitges, Spain

Visit our events page to see a complete list of events in the pancreatic cell community.
NEW Postdoctoral Position – Diabetes Complications (Novo Nordisk)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

PhD Position – Pancreatic Diseases (University Hospital Zurich)

Postdoctoral Position – Metabolic Fingerprinting of Gestational Diabetes Mellitus (CEU San Pablo University)

Postdoctoral Position – Cancer (MD Anderson Cancer Center)

Research Fellow – Systems Biology (University of Glasgow)

PhD Studentships – Diabetes Research (Diabetes UK)

Postdoctoral Position – Obesity and Diabetes Research (University of Iowa)

Postdoctoral Research Fellow – Mechanisms of Cell Death of Normal Tissue Stem Cells (Memorial Sloan Kettering Cancer Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pancreatic Cell News: Archives | Events | Contact Us